CD4 and neoplasm: rGL261 alone showed weaker T cell activation than the rGL261‐MBTA vaccine group upon PMA treatment (Figure 3E,F), consistent with the weak immunogenicity of irradiated tumor cells previously reported.[12] Notably, the MBTA alone group showed comparable cytotoxic signatures (IFNγ+TNFα+ and Granzyme B+) in the CD4 and CD8 T cells after PMA activation, compared to the rGL261‐MBTA vaccine group.